# US 2008/0305472 A1 · Method of detecting influenza bacillus, primer set for detection of influenza bacillus and kit for detection of influenza bacillus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0305472 A1
- Document ID: US20080305472A1
- Status: Published application
- Kind: A1
- Application number: 11/665,566
- Filed: 2005-05-16
- Published: 2008-12-11
- Earliest claimed: 2004-10-19
- Assignees: Nihon University
- Inventors: Mitsuko Seki; Hirotaka Torigoe
- Web page: https://patentgrep.com/patent/US20080305472A1

## CPC

- C12Q 1/701: {Specific hybridization probes}
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention provides a method of detecting Haemophilus influenzae, which enables accurate and rapid detection of H. influenzae, a primer set for detecting H. influenzae, and a kit for detecting H. influenzae. Nucleic acid amplification is carried out using the DNA of H. influenzae as a template, and also using the LAMP primers as shown in SEQ ID NOS: 1 to 5 given as examples of the present invention. Thus, the presence or absence of the amplified product is detected. When primers having sequences that are complementary to the sequences as shown in SEQ ID NOS: 1 to 5 are used, such primers are excellent in terms of detection sensitivity and promptness of detection, as well as specificity. In addition, as another example of the present invention, nucleic acid amplification is carried out using LAMP primers as shown in SEQ ID NOS: 43 to 47, and the presence or absence of the amplified product is detected. Thereby, H. influenzae Type b can be distinguished from other capsular serotype and non-encapsulated type H. influenzae, and it can be detected rapidly, simply, and accurately.

## Claims

### Claim 1

A method of detecting Haemophilus influenzae based on the presence or absence of nucleic acid amplification as a result of a nucleic acid amplification reaction using a primer set,
which is characterized in that a LAMP primer set is used as said primer set, wherein all primers have a nucleotide sequence that is identical to or complementary to a partial nucleotide sequence in a nucleotide region located downstream of bp 90 of the P6 protein gene of Haemophilus influenzae, and
wherein at least one primer has a nucleotide sequence that is identical to or complementary to a partial nucleotide sequence in the nonhomologous region ranging from bp 90 to 183, or from bp 337 to 462 of the P6 protein gene of Haemophilus influenzae.

### Claim 2 (depends on 1)

The method of detecting Haemophilus influenzae according to claim 1, which is characterized in that said LAMP primer set is any one of LAMP primer sets comprising the primers as described in the following (a) to (r):
(a) 4 types of primers each having a nucleotide sequence that is identical to or substantially identical to each of the nucleotide sequences as shown in SEQ ID NOS: 1 to 4 in the sequence listing;
(b) 4 types of primers each having a nucleotide sequence that is complementary to each of the nucleotide sequences as described in (a) above;
(c) 4 types of primers each having a nucleotide sequence that is identical to or substantially identical to each of the nucleotide sequences as shown in SEQ ID NOS: 6 to 9;
(d) 4 types of primers each having a nucleotide sequence that is complementary to each of the nucleotide sequences as described in (c) above;
(e) 4 types of primers each having a nucleotide sequence that is identical to or substantially identical to each of the nucleotide sequences as shown in SEQ ID NOS: 7 to 9 and 11;
(f) 4 types of primers each having a nucleotide sequence that is complementary to each of the nucleotide sequences as described in (e) above;
(g) 4 types of primers each having a nucleotide sequence that is identical to or substantially identical to each of the nucleotide sequences as shown in SEQ ID NOS: 15 to 18;
(h) 4 types of primers each having a nucleotide sequence that is complementary to each of the nucleotide sequences as described in (g) above;
(i) 4 types of primers each having a nucleotide sequence that is identical to or substantially identical to each of the nucleotide sequences as shown in SEQ ID NOS: 20 to 23;
(j) 4 types of primers each having a nucleotide sequence that is complementary to each of the nucleotide sequences as described in (i) above;
(k) 4 types of primers each having a nucleotide sequence that is identical to or substantially identical to each of the nucleotide sequences as shown in SEQ ID NOS: 24 to 27;
(l) 4 types of primers each having a nucleotide sequence that is complementary to each of the nucleotide sequences as described in (k) above;
(m) 4 types of primers each having a nucleotide sequence that is identical to or substantially identical to each of the nucleotide sequences as shown in SEQ ID NOS: 26 and 28 to 30;
(n) 4 types of primers each having a nucleotide sequence that is complementary to each of the nucleotide sequences as described in (m) above;
(o) 4 types of primers each having a nucleotide sequence that is identical to or substantially identical to each of the nucleotide sequences as shown in SEQ ID NOS: 26 and 30 to 32;
(p) 4 types of primers each having a nucleotide sequence that is complementary to each of the nucleotide sequences as described in (O) above;
(q) 4 types of primers each having a nucleotide sequence that is identical to or substantially identical to each of the nucleotide sequences as shown in SEQ ID NOS: 33 to 36; and
(r) 4 types of primers each having a nucleotide sequence that is complementary to each of the nucleotide sequences as described in (q) above.

### Claim 3 (depends on 2)

The method of detecting Haemophilus influenzae according to claim 2, which is characterized in that said LAMP primer set is any one of LAMP primer sets comprising the primers as described in the following (s) to (x):
(s) the 4 types of primers according to claim 2(a), and a primer having a nucleotide sequence that is identical to or substantially identical to the nucleotide sequence as shown in SEQ ID NO: 5 in the sequence listing;
(t) the 4 types of primers according to claim 2(b), and a primer having a nucleotide sequence that is identical to or substantially identical to a nucleotide sequence complementary to the nucleotide sequence as shown in SEQ ID NO: 5 in the sequence listing;
(u) the 4 types of primers according to claim 2(c), and a primer having a nucleotide sequence that is identical to or substantially identical to the nucleotide sequence as shown in SEQ ID NO: 10 in the sequence listing;
(v) the 4 types of primers according to claim 2(d), and a primer having a nucleotide sequence that is identical to or substantially identical to a nucleotide sequence complementary to the nucleotide sequence as shown in SEQ ID NO: 10 in the sequence listing;
(w) the 4 types of primers according to claim 2(g), and a primer having a nucleotide sequence that is identical to or substantially identical to the nucleotide sequence as shown in SEQ ID NO: 19 in the sequence listing; and
(x) the 4 types of primers according to claim 2(h), and a primer having a nucleotide sequence that is identical to or substantially identical to a nucleotide sequence complementary to the nucleotide sequence as shown in SEQ ID NO: 19 in the sequence listing.

### Claim 4

A method of detecting Haemophilus influenzae Type b based on the presence or absence of nucleic acid amplification as a result of a nucleic acid amplification reaction using a primer set,
which is characterized in that a LAMP primer set is used as said primer set, wherein all primers have a nucleotide sequence that is identical to or complementary to a partial nucleotide sequence in the region ranging from bp 1 to 6653 of the capsulation locus region II of the Haemophilus influenzae Type b.

### Claim 5 (depends on 4)

The method of detecting Haemophilus influenzae according to claim 4, which is characterized in that a LAMP primer set is used as said LAMP primer set, wherein all primers have a nucleotide sequence that is identical to or complementary to a partial nucleotide sequence in the region ranging from bp 5,000 to 6,653 of said capsulation locus region II.

### Claim 6 (depends on 5)

The method of detecting Haemophilus influenzae according to claim 5, which is characterized in that said LAMP primer set is any one of LAMP primer sets comprising the primers as described in the following (A) to (R):
(A) 4 types of primers each having a nucleotide sequence that is identical to or substantially identical to each of the nucleotide sequences as shown in SEQ ID NOS: 43 to 46 in the sequence listing;
(B) 4 types of primers each having a nucleotide sequence that is complementary to each of the nucleotide sequences as described in (A) above;
(C) 4 types of primers each having a nucleotide sequence that is identical to or substantially identical to each of the nucleotide sequences as shown in SEQ ID NOS: 48 to 51;
(D) 4 types of primers each having a nucleotide sequence that is complementary to each of the nucleotide sequences as described in (C) above;
(E) 4 types of primers each having a nucleotide sequence that is identical to or substantially identical to each of the nucleotide sequences as shown in SEQ ID NOS: 53 to 56;
(F) 4 types of primers each having a nucleotide sequence that is complementary to each of the nucleotide sequences as described in (E) above;
(G) 4 types of primers each having a nucleotide sequence that is identical to or substantially identical to each of the nucleotide sequences as shown in SEQ ID NOS: 58 to 61;
(H) 4 types of primers each having a nucleotide sequence that is complementary to each of the nucleotide sequences as described in (G) above;
(I) 4 types of primers each having a nucleotide sequence that is identical to or substantially identical to each of the nucleotide sequences as shown in SEQ ID NOS: 62 to 65;
(J) 4 types of primers each having a nucleotide sequence that is complementary to each of the nucleotide sequences as described in (I) above;
(K) 4 types of primers each having a nucleotide sequence that is identical to or substantially identical to each of the nucleotide sequences as shown in SEQ ID NOS: 67 to 70;
(L) 4 types of primers each having a nucleotide sequence that is complementary to each of the nucleotide sequences as described in (K) above;
(M) 4 types of primers each having a nucleotide sequence that is identical to or substantially identical to each of the nucleotide sequences as shown in SEQ ID NOS: 71 to 74;
(N) 4 types of primers each having a nucleotide sequence that is complementary to each of the nucleotide sequences as described in (M) above;
(O) 4 types of primers each having a nucleotide sequence that is identical to or substantially identical to each of the nucleotide sequences as shown in SEQ ID NOS: 73 to 76;
(P) 4 types of primers each having a nucleotide sequence that is complementary to each of the nucleotide sequences as described in (O) above;
(O) 4 types of primers each having a nucleotide sequence that is identical to or substantially identical to each of the nucleotide sequences as shown in SEQ ID NOS: 73, 74, 77, and 78; and
(R) 4 types of primers each having a nucleotide sequence that is complementary to each of the nucleotide sequences as described in (O) above.

### Claim 7 (depends on 6)

The method of detecting Haemophilus influenzae according to claim 6, which is characterized in that said LAMP primer set is any one of LAMP primer sets comprising the primers as described in the following (S) to (Z):
(S) the 4 types of primers according to claim 6(A), and a primer having a nucleotide sequence that is identical to or substantially identical to the nucleotide sequence as shown in SEQ ID NO: 47 in the sequence listing;
(T) the 4 types of primers according to claim 6(B), and a primer having a nucleotide sequence that is identical to or substantially identical to a nucleotide sequence complementary to the nucleotide sequence as shown in SEQ ID NO: 47 in the sequence listing;
(U) the 4 types of primers according to claim 6(C), and a primer having a nucleotide sequence that is identical to or substantially identical to the nucleotide sequence as shown in SEQ ID NO: 52 in the sequence listing;
(V) the 4 types of primers according to claim 6(D), and a primer having a nucleotide sequence that is identical to or substantially identical to a nucleotide sequence complementary to the nucleotide sequence as shown in SEQ ID NO: 52 in the sequence listing;
(W) the 4 types of primers according to claim 6(E), and a primer having a nucleotide sequence that is identical to or substantially identical to the nucleotide sequence as shown in SEQ ID NO: 57 in the sequence listing;
(X) the 4 types of primers according to claim 6(F), and a primer having a nucleotide sequence that is identical to or substantially identical to a nucleotide sequence complementary to the nucleotide sequence as shown in SEQ ID NO: 57 in the sequence listing;
(Y) the 4 types of primers according to claim 6(I), and a primer having a nucleotide sequence that is identical to or substantially identical to the nucleotide sequence as shown in SEQ ID NO: 66 in the sequence listing; and
(Z) the 4 types of primers according to claim 6(J), and a primer having a nucleotide sequence that is identical to or substantially identical to a nucleotide sequence complementary to the nucleotide sequence as shown in SEQ ID NO: 66 in the sequence listing.

### Claim 8 (depends on 1, 4)

A primer set for detecting Haemophilus influenzae, which is characterized in that it is any one of the LAMP primer sets according to claim 1 or 4.

### Claim 9 (depends on 1, 4)

A kit for detecting Haemophilus influenzae, which is characterized in that it comprises the LAMP primer sets according to claim 1 or 4.
